What happens to your blood sugar after a meal might have a bigger effect on your brain health in later life than many people realise. Scientists at the University of Liverpool have found that sharp rises in glucose levels following meals are linked... (Audio Available – 639 words – 3 minute read time)
Novo Nordisk announced on 24 November 2025 the end of its phase 3 EVOKE and EVOKE+ trials, which investigated oral semaglutide – the active ingredient in Rybelsus, approved for type 2 diabetes – as a potential treatment... (Audio Available – 365 words – 2 minute read time)
For years, Alzheimer’s research has focused on A-beta and tau amyloids, which harm neurons and impair brain function. A recent study from Johns Hopkins University suggests these plaques may not act alone
At the European Academy of Neurology Congress in Helsinki, researchers unveiled a ground breaking blood test that could revolutionize Alzheimer’s disease management by identifying
Two innovative Alzheimer’s drugs, Donanemab and Lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending